Summary of Conference Call on ADC Industry Industry Overview - The A-share and H-share pharmaceutical sectors experienced a pullback after September 10, 2025, currently in a state of fluctuation, but confidence in domestic innovative drugs remains strong, with low-expectation BD projects gaining renewed attention, significantly boosting company stock prices [1][4][5] - Global BD and M&A activities increased significantly in 2025, reflecting the demand for new pipelines from large pharmaceutical companies, with Chinese enterprises playing a crucial role in global BD activities, indicating a trend towards consolidation in the pharmaceutical industry [1][5] Core Insights on ADC Technology - ADC technology has evolved through several generations, with domestic companies showing clear advantages in optimizing ADCs through engineering methods to improve antibodies, linkers, and toxins, potentially replacing traditional chemotherapy and enhancing treatment efficacy [1][7] - In 2026, a large number of key clinical trial data for ADCs combined with bispecific antibodies are expected to be released, with new targets, toxins, and drug forms driving industry development and providing positive catalysts for the market [1][8] Clinical Data and Market Performance - In 2025, significant clinical data was released in the ADC industry, enhancing market confidence, particularly with the XBI index showing strong performance post-September, reflecting high market interest in innovative drugs [3] - ADCs demonstrated significant survival benefits in first-line treatments, with long-term OS data showing promising results, indicating that more first-line treatments may be led by ADCs in the future [2][13] Safety and Efficacy Challenges - While ADCs show superior efficacy compared to traditional chemotherapy, they still face safety challenges, such as the risk of infections or ocular toxicity from MNAE products, making the management of side effects by physicians crucial [9][10] - The importance of managing side effects is emphasized, as adverse reactions typically do not threaten patient life, and better management strategies are expected to evolve with increased clinical application [10][11] Key Considerations for ADC Platforms - When selecting ADC platforms, it is essential to focus on early clinical data and the controllability of safety issues, as historical data indicates strong continuity in clinical outcomes from phase I to phase II trials [12] Future Trends and Catalysts - Looking ahead to 2026 and beyond, two main trends are anticipated: the rapid support of more positive data for large indication first-line treatments and the emergence of more data on ADCs used in combination with other drugs [14] - New ADCs targeting novel mechanisms and indications are expected to emerge, with companies exploring combinations of therapies for autoimmune diseases and addressing resistance in hard-to-treat targets [15][17] Promising Companies in ADC Development - Notable ADC development companies include Kelun-Biotech, BaiLi Tianheng, and YingEn, with promising products like Kelun-Biotech's CHOP2 ADC and BaiLi Tianheng's bispecific ADC showing strong performance [18] - Pfizer's ADC products, particularly those utilizing MMAE technology, are still considered valuable despite recent trends favoring other approaches, indicating ongoing potential in their efficacy against certain epithelial tumors [18]

来源：华泰证券策略研究 本周港股市场窄幅波动，呈现磨底迹象。当前市场已接近"利空出尽"状态，前期压制的核心风险点如中 美贸易摩擦、海外流动性宽松交易回摆及"外卖大战"对互联网板块盈利的冲击已在回调过程中释放相对 充分，因此当前市场点位下行空间相对有限。情绪指标在悲观区间反复震荡或表明市场依然缺乏主线催 化，总体指向左侧布局机会。配置上可关注基本面改善的线索，建议关注彭博一致盈利预期有所上行的 大众消费，以及此前在外流动性压制下调整相对充分，三季报公布后盈利预期稳定的港股医药及互联网 板块。 风险提示：AI推进速度不及预期，12月资金面偏紧导致波动放大。 多数此前压制市场的负面因素释放相对充分 1）中美关系方面，中美元首会晤后双边经贸关系暂稳，上周中美元首再通话，特朗普24日在其社交媒 体上表示或于2026年两次访华，短期不确定风险持续降温；2）海外流动性方面，降息预期的回摆交易 已相对充分，12月FOMC降息概率重新回升至80%上方；政府关门结束和缩表停止后美元流动性压制权 益资产表现的峰值或已过去；3）企业盈利方面，市场过去担忧的"外卖大战"对头部互联网企业冲击"达 峰"。上周阿里财报发布后股价相对稳定且电 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [1]. Core Insights - The overseas small nucleic acid market is entering a harvest period, with a focus on domestic companies such as Yuyuan, Frontier, and Fuyuan [1][16]. - The A-share pharmaceutical index has increased by 2.67% this week and 16.72% year-to-date, outperforming the CSI 300 by 1.03% and 1.68% respectively [4][9]. - The report highlights significant advancements in small nucleic acid drug technologies, expanding their application beyond rare diseases to chronic conditions such as cardiovascular diseases and metabolic disorders [16][18]. Summary by Sections Industry Trends - The report notes that various pharmaceutical sectors, including raw materials (+4.27%), chemical pharmaceuticals (+4.19%), and medical devices (+2.30%), have seen stock price increases [4][9]. - Key companies with notable stock performance include Haiwang Biological (+38.2%) and Guangdong Wannianqing (+36.2%) [4][9]. Research and Development Progress - Significant drug approvals include the self-immune new drug "Pikangqibai" by Innovent Biologics and the BCL2 inhibitor "Sotokura" by BeiGene, both of which have received regulatory approval [4]. - The report emphasizes the importance of delivery systems in the development of small nucleic acid drugs, with a focus on companies like Yuyuan Pharmaceutical and Frontier Biotech [16][18]. Market Insights and Regulatory Dynamics - The report ranks promising sub-industries as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12]. - Specific stock recommendations include Yuyuan Pharmaceutical, Frontier Biotech, and Heng Rui Medicine among others, based on their innovative drug pipelines and market potential [12][18].

行 业 研 究 华福证券 医药生物 2025 年 11 月 30 日 解析国内小核酸研发格局（靶点、技术路线和适 应症） 投资要点： 风险提示：行业需求不及预期；公司业绩不及预期；市场竞争加剧风险。 医药生物 强于大市（维持评级） 一年内行业相对大盘走势 团队成员 分析师： 陈铁林(S0210524080007) ctl30598@hfzq.com.cn 行 业 定 期 报 告 行情回顾：本周（2025 年 11 月 24 日- 2025 年 11 月 28 日）中信医药 指数上涨 2.7%，跑赢沪深 300 指数 1.0pct，在中信一级行业分类中排名第 16 位；2025 年初至今中信医药生物板块指数上涨 17.7%，跑赢沪深 300 指 数 2.7pct，在中信行业分类中排名第 15 位。本周涨幅前五的个股为：海王 生物（+38.2%）、粤万年青（+36.2%）、广济药业（+31.7%）、金迪克（+31.3%）、 前沿生物（+23.1%）。 小核酸行业更新：国内小核酸研发格局分析——寻找有竞争力的靶点、 技术路线和适应症。本周梳理了国内小核酸药物的研发格局，（1）在成熟 靶点布局方面，重点聚焦在心血管、 ...

Investment Rating - The report maintains an investment rating of "Outperform" [5] Core Insights - The innovative drug sector is experiencing rapid growth, with several new drugs being quickly incorporated into the medical insurance directory as of October 2025 [3][20] - The report highlights significant increases in the number of drugs entering hospitals, particularly those newly included in the insurance directory, indicating strong market demand [3][19] Weekly New Drug Market Review - From November 24 to November 30, 2025, the top five performing new drug companies were: Frontline Bio (+23.12%), Yifang Bio (+15.74%), Rongchang Bio (+15.39%), Kangfang Bio (+14.86%), and Jakes (+14.18%). The five companies with the largest declines were: Yongtai Bio (-4.11%), Nothland (-3.33%), Junshengtai (-2.78%), Boan Bio (-2.09%), and Dongyao Pharma (-1.11%) [1][14] Suggested Focus Stocks - The report suggests focusing on several companies with promising catalysts, including: 1. Companies with MNC certification and high overseas sales potential: Sanofi, Lianbang Pharma, and Kelun Biotech 2. Companies with overseas data catalysts: Betta Pharma, Hutchison China MediTech, and Yimeng Bio 3. Potential heavyweights for overseas MNC licensing: Fuhong Hanlin, Shiyao Group, and Yifang Bio 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18] New Drug Industry Key Analysis - The National Healthcare Security Administration updated the data on innovative drugs included in the insurance directory as of October 2025, showing rapid hospital entry for several newly included domestic innovative drugs. Notable drugs with fast entry rates include: - Hengrui Medicine's Tazobactam - Innovent Biologics' Toripalimab - Haisco's Alogliptin and Clopidogrel - Sinopharm's Aliskiren and Amlodipine - Shanghai Yizhong's Paclitaxel polymer micelles - Kangfang Bio's Ivoris monoclonal antibody [3][19] New Drug Approval and Acceptance Status - This week, 11 new drugs or new indications received approval for market entry, while 13 new drugs or new indications were accepted for review [4][24] New Drug Clinical Application Approval and Acceptance Status - This week, 54 new drug clinical applications were approved, and 44 new drug clinical applications were accepted [8][27]

Market Overview - The Hang Seng Index opened high but experienced a decline, closing down 0.24% by midday [1] - The internet sector showed the strongest performance, followed by technology and consumer sectors, while healthcare and banking sectors faced declines [1] Internet Sector - The internet sector opened slightly higher and maintained a narrow range above the midline, rising 0.57% by midday [3] - Notable performers included Horizon Robotics with a 3.31% increase, while companies like JD Group, Baidu, and Alibaba also saw slight gains [3] - Conversely, stocks such as Bilibili, Kuaishou, and Meituan experienced minor declines [3] Consumer Sector - The consumer sector opened high but fell back, showing a slight increase of 0.07% by midday [3] - Significant gains were observed in Pop Mart, which surged 3.84%, and MGM, which rose 3.3%, with several other stocks like Mixue Ice City and金沙江 also increasing by over 2% [3] - However, Hansoh Pharmaceutical dropped 3.17%, and other companies like Nongfu Spring, Sinopharm, and Alibaba Health saw declines exceeding 2% [3] Healthcare Sector - The healthcare sector experienced a sharp decline after opening, maintaining a weak consolidation at low levels, down 0.96% by midday [3] - WuXi Biologics faced a significant drop of 3.9%, with nearly 10 stocks including CanSino Biologics, JD Health, and 3SBio also declining by over 1% [3]

Core Viewpoint - The Hong Kong innovative drug sector has experienced a significant rally this year, with the Hong Kong innovative drug index (CSI:931787) rising by 75% until October, but has since entered a cooling phase as investors digest previous gains [3][4]. Group 1: Market Performance - The innovative drug sector saw 23 companies listed in the Hong Kong healthcare sector this year, compared to only 8 last year [3]. - Despite the initial surge, many companies that have not yet entered the Stock Connect are experiencing a decline in stock prices, indicating a challenging path to inclusion [3][4]. Group 2: Stock Connect Mechanism - The Stock Connect allows mainland investors to trade Hong Kong-listed stocks, with significant contributions from southbound funds, accounting for 40%-50% of trading volume in some companies [3][4]. - Companies not included in the Stock Connect face liquidity challenges, as most mainland public funds cannot invest directly [4][5]. Group 3: Challenges for Inclusion - The threshold for entering the Stock Connect has increased due to rising market valuations, with the market capitalization requirement for inclusion in the Hang Seng Composite Index set at approximately HKD 9.32 billion [6]. - Companies previously included in the Stock Connect but later removed face significant hurdles to re-entry, as liquidity issues persist [7][8]. Group 4: Business Development (BD) Fatigue - The market has shown signs of "BD fatigue," where announcements of potential business developments no longer lead to significant stock price increases, as seen with recent collaborations that resulted in stock declines [9][10]. - Investors are now demanding more substantial evidence of project viability and commitment from partners before reacting positively to BD announcements [10]. Group 5: Future Outlook - The market is currently in a quiet phase, with investors waiting for clear signals of recovery before increasing their positions, reflecting a cautious sentiment as year-end approaches [10][11].

Group 1 - A fire incident occurred in Hong Kong's Tai Po district, resulting in significant casualties and drawing nationwide attention [1] - The company, Shijiazhuang Pharmaceutical Group, has initiated an emergency relief plan, actively communicating with government departments [1] - The company has donated HKD 10 million in cash and medicines to support the urgent needs of affected individuals for emergency housing and basic living security during the transition period [1]

Group 1: Investment Ratings - The report maintains a "Buy" rating for both Ctrip and Tongcheng Travel, indicating a positive outlook on their performance in the online travel industry [1][2][5][6]. Group 2: Core Insights - Ctrip's Q3 2025 revenue increased by 16% year-on-year to 18.4 billion yuan, with non-GAAP operating profit reaching 6.1 billion yuan, exceeding expectations due to lower marketing expenses [1][5]. - Tongcheng Travel reported a 10% year-on-year revenue growth to 5.5 billion yuan in Q3 2025, with adjusted net profit rising 17% to 1.06 billion yuan, driven by better-than-expected accommodation business performance [2][6]. - Ctrip's accommodation booking revenue grew by 18%, transportation revenue by 12%, and international OTA platform bookings increased by over 60% year-on-year [1][5]. - Tongcheng Travel's core OTA business revenue grew by 15%, with accommodation booking revenue also up by 15%, benefiting from increased hotel average prices and record daily room nights [2][6]. - Ctrip's international hotel and flight bookings have increased by 140% compared to 2019, while Tongcheng Travel expects outbound travel business to grow rapidly, contributing 10-15% to overall revenue by 2027 [1][2][5][6]. Group 3: Summary by Sections Section 1: Overseas Social Services - Ctrip's Q3 2025 performance shows strong growth across various segments, with significant increases in international bookings and a solid market position in China [1][5]. - Tongcheng Travel's performance reflects a robust growth trajectory, particularly in accommodation and outbound travel, with a strong user base [2][6]. Section 2: Overseas Pharmaceuticals - CSPC Pharmaceutical Group reported a 12.3% year-on-year decline in revenue for the first three quarters of 2025, totaling 19.89 billion yuan, but showed a 3.4% revenue growth in Q3 [3][10]. - The company's net profit for Q3 2025 increased by 27.2% to 964 million yuan, aligning with expectations despite a decline in overall revenue for the year [3][10]. Section 3: Overseas Education - The education index saw a 2% increase, with a year-to-date growth of 7.3%, indicating a recovery in the sector [4][16]. - The report suggests a positive outlook for private higher education companies, with expectations of improved profitability and growth potential [4][18].

Investment Rating - The report maintains a "Buy" rating for both Ctrip and Tongcheng Travel, indicating a positive outlook for their performance in the online travel industry [2][3]. Core Insights - Ctrip's 3Q25 revenue increased by 16% year-on-year to 18.4 billion yuan, with a non-GAAP operating profit of 6.1 billion yuan, exceeding expectations due to lower marketing expenses [2][7]. - Tongcheng Travel's 3Q25 revenue grew by 10% year-on-year to 5.5 billion yuan, with adjusted net profit rising 17% to 1.06 billion yuan, driven by better-than-expected accommodation business performance [3][8]. - Both companies are expected to benefit from the recovery in outbound tourism, with Ctrip's international OTA platform bookings increasing over 60% year-on-year and inbound tourism bookings more than doubling [2][7]. - The report highlights the stability of the online travel industry and the potential for market share growth for both companies, particularly in international markets [2][3]. Summary by Sections 1. Overseas Social Services: Ctrip and Tongcheng Travel 3Q25 Performance - Ctrip's accommodation booking revenue rose by 18%, transportation revenue by 12%, and business travel management revenue by 15% [2][7]. - Tongcheng Travel's core OTA business revenue increased by 15%, with accommodation booking revenue also up by 15% [3][8]. - Both companies are positioned well for future growth, particularly in outbound travel, with expectations for international flight and hotel contributions to increase significantly by 2027 [3][8]. 2. Overseas Pharmaceuticals: CSPC Pharmaceutical Group - CSPC's revenue for the first three quarters of 2025 decreased by 12.3% to 19.89 billion yuan, but third-quarter revenue grew by 3.4% to 6.62 billion yuan, aligning with expectations [4][13]. - The report notes a decline in gross margin and a decrease in the contribution of the prescription drug segment to total sales [4][13]. 3. Overseas Education: Profitability Management Conditions Mature - The education index rose by 2% this week, with a year-to-date increase of 7.3% [19]. - The report suggests focusing on Hong Kong higher education companies, anticipating a recovery in profitability and expansion potential [21][29].